- 249
- 37 336
HealthTree Foundation for Blood Cancers
United States
Приєднався 27 кві 2022
HealthTree Foundation empowers patients with blood cancers at each step of their disease journey - from diagnosis, through education, care and on to a cure. The HealthTree Foundation does this through three areas of support; simplified patient education, support research driven by patient needs, and the use of data to solve patient and research problems.
ACA Changes and Medicaid Expansion: What Blood Cancer Patients Need to Know and How to Stay Prepared
Join our webinar for blood cancer patients on ACA changes, Medicaid expansion, and strategies to safeguard healthcare with expert Diahanna Vallentine.
Recorded on January 7th, 2024 as part of the Financial Education Group in the Educational Webinar Program by HealthTree with Diahanna Vallentine.
The HealthTree Foundation brings information from the experts to the patients! Learn more at healthtree.org/
Donate to the HealthTree Foundation or learn more about additional blood cancer support we offer here: give.healthtree.org/campaign/50-days-to-usd500k/c536306
HealthTree Cure Hub helps you find your best treatment options and accelerate cure for blood cancers. Join today at www.healthtree.org/
Recorded on January 7th, 2024 as part of the Financial Education Group in the Educational Webinar Program by HealthTree with Diahanna Vallentine.
The HealthTree Foundation brings information from the experts to the patients! Learn more at healthtree.org/
Donate to the HealthTree Foundation or learn more about additional blood cancer support we offer here: give.healthtree.org/campaign/50-days-to-usd500k/c536306
HealthTree Cure Hub helps you find your best treatment options and accelerate cure for blood cancers. Join today at www.healthtree.org/
Переглядів: 15
Відео
Allogeneic & Autologous Stem Cell Transplant for Follicular Lymphoma | Yasmina Serroukh, MD | #ASH24
Переглядів 1212 годин тому
Dr Yasmina Serroukh discusses a study looking at outcomes with stem cell transplantation for patients with follicular lymphoma. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: Outcome of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma, a Benchmark Study from the Lymphoma Working Party of the European Society for Blood and M...
Odronextamab as First-Line Therapy in Follicular Lymphoma | Rueme Birhiray, MD | #ASH24
Переглядів 1012 годин тому
Dr Rueme Birhiray discusses a new class of drug, bispecific antibodies, for patients with follicular lymphoma, specifically studies looking at odronextamab. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the ...
Phase 3 Asciminib Tolerability Trial , ASC4FIRST, for Patients with CML | David Andorsky |#ASH2024
Переглядів 512 годин тому
Dr David Andorsky discusses the ASC4FIRST trial looking at the safety and tolerability of asciminib. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: Asciminib (ASC) Demonstrates Favorable Safety and Tolerability Compared with Each Investigator-Selected Tyrosine Kinase Inhibitor (IS TKI) in Newly Diagnosed Chronic Myeloid Leukemia in Chroni...
The Phase 2 ASC2ESCALATE Trial Evaluating Asciminib for CML Patients | David Andorsky, MD | #ASH2024
Переглядів 1012 годин тому
Dr David Andorsky discusses the phase 2 ASC2ESCALATE trial looking at the efficacy of ascminib. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Ki...
Race, Ethnicity, and Socioeconomics Tied to Disparities in Myelofibrosis | Anand Patel, MD | #ASH24
Переглядів 812 годин тому
Dr Anand Patel discusses a study done in Chicago to understand disparities affecting patients with myelofibrosis. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: 3794 Assessing Disparities in a Chicagoland Cohort of Patients with Myelofibrosis #ASH24 #Myelofibrosis #mpnsm Follow HealthTree: linktr.ee/HealthTreeUniversity
Fedratinib Helps Myelofibrosis Patients with Low Platelet Counts | Haifa Katrhin Al-Ali, MD | #ASH24
Переглядів 712 годин тому
Dr Haifa Kathrin Al-Ali discusses how JAK2 inhibitors, specifically fedratinib, could help myelofibrosis patients with low platelet counts. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: Efficacy and Safety of Fedratinib in Patients with Myelofibrosis and Low Baseline Platelet Counts in the Phase 3 Randomized FREEDOM2 Trial #ASH24 #Myelof...
BTK Degrader Study Shows Promise for a New Class of CLL Therapies | Alexey Danilov MD PhD | #ASH2024
Переглядів 1412 годин тому
Dr Alexey Danilov presents a study on two promising BTK degraders for patients with CLL. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: Nx-2127 and Nx-5948, Two Clinical Stage Cereblon-Recruiting BTK Degraders, Facilitate T Cell Functionality in Chronic Lymphocytic Leukemia #ASH24 #CLL #leusm Follow HealthTree: linktr.ee/HealthTreeUniversity
Duration of BTKi therapy correlates with time to next treatment in CLL | Kerry Rogers, MD | #ASH24
Переглядів 1112 годин тому
Dr Kerry Rogers discusses what the outcomes of patients on BTK inhibitors are and what the outcomes are if they need to stop treatment. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects #ASH24 #CLL #leusm Follow Healt...
Quality of Life Dispairities for Patients with MDS | Somedeb Ball, MBBS | #ASH24
Переглядів 412 годин тому
Dr Somedeb Ball discusses the disparities on quality of life for patients with myelodysplastic syndromes. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: A Prospective Evaluation of Impact of Disease, Treatment, Sex, and Race Disparities on Quality of Life and Financial Toxicity in Patients with Myelodysplastic Syndromes #ASH24 #MDS #mdssm...
Importance of Support for Caregivers of Transfusion Dependent Patients | Maria Diez-Campelo | #ASH24
Переглядів 812 годин тому
Dr Maria Diez-Campelo discusses the type of support caregivers need when caring for a patient who is receiving transfusion treatments. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: The Burden of Transfusion Dependence on Caregivers of Patients with Lower-Risk Myelodysplastic Syndromes in North America and Europe #ASH24 #MDS #mdssm Follow...
Benefits of Thorough Evaluations Before Starting AML Treatment | Samuel Yates, MD, MS | #ASH24
Переглядів 912 годин тому
Dr. Samuel Yates from the University of Chicago discusses the potential benefits of waiting for thorough evaluations before starting treatment for acute myeloid leukemia. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Mul...
Impact of Transplant Timing in MDS Treatment | Benajmin Rolles, MD | #ASH24
Переглядів 512 годин тому
Dr Benjamin Rolles discusses the impact of hypomethylating agents with MDS patients. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MD...
How Self-Rated Health Impacts Patient Outcomes| Nora Balas, PhD | #ASH24
Переглядів 112 годин тому
Dr Nora Balas discusses how patient self-rated health can impact mortality rates after transplant and why getting good exercise, managing pain well, and having good support for mental health can help improve outcomes. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: Self-Rated Health Is an Independent Predictor of Subsequent Late Mortality ...
Examining 3 Key Studies on Treatments for AML and ALL | Jayastu Senapati, MD, MBBS | #ASH24
Переглядів 1512 годин тому
Dr Jayastu Senapati covers three studies, one looking at Core Binding Factor Acute Myeloid Leukemia, a smaller subset of AML, and the treatment regimens being investigated, and two looking at Acute Lymphoblastic Leukemia and what treatments are being investigated for adult patients with ALL. Link to ASH playlist: healthtree.org/blood-cancer/university/modules/V33aLCfmYhGeYz3iLH8b ASH Abstract: ...
Inpatient or Outpatient Consolidation Therapy: Which is Better?| Leora Boussi, MD | #ASH24
Переглядів 512 годин тому
Inpatient or Outpatient Consolidation Therapy: Which is Better?| Leora Boussi, MD | #ASH24
Racial Disparities in Youth and Young Adults with AML | Erin Feliciano, MD | #ASH24
Переглядів 3312 годин тому
Racial Disparities in Youth and Young Adults with AML | Erin Feliciano, MD | #ASH24
AML: New Strategies For Preventing Graft vs Host Disease | Giorgia Battipaglia, MD | #ASH24
Переглядів 1312 годин тому
AML: New Strategies For Preventing Graft vs Host Disease | Giorgia Battipaglia, MD | #ASH24
Revumenib: New Approved Drug for Relapsed/Refractory Acute Leukemia Patients | Eytan Stein | #ASH24
Переглядів 1412 годин тому
Revumenib: New Approved Drug for Relapsed/Refractory Acute Leukemia Patients | Eytan Stein | #ASH24
Impact of Hospital Readmission on Quality of Life in AML | Ayobami Olafimihan, MD | #ASH24
Переглядів 412 годин тому
Impact of Hospital Readmission on Quality of Life in AML | Ayobami Olafimihan, MD | #ASH24
Good Responses to Phase 2 CLIA + Ven Therapy for Acute Myeloid Leukemia | Tapan Kadia, MD | #ASH24
Переглядів 812 годин тому
Good Responses to Phase 2 CLIA Ven Therapy for Acute Myeloid Leukemia | Tapan Kadia, MD | #ASH24
Menin Inhibitor Study Results: Ziftomenib for Newly Diagnosed AML Patients | Amer Zeidan | #ASH24
Переглядів 812 годин тому
Menin Inhibitor Study Results: Ziftomenib for Newly Diagnosed AML Patients | Amer Zeidan | #ASH24
VEN + IVO + AZA Combination Therapy in IDH1-Mutated AML, MDS & MPNs | Jennifer Marvin Peek | #ASH24
Переглядів 912 годин тому
VEN IVO AZA Combination Therapy in IDH1-Mutated AML, MDS & MPNs | Jennifer Marvin Peek | #ASH24
CAR-T Cell Therapy for Transformed Follicular Lymphoma | Matthew Cortese, MD | #ASH24
Переглядів 1212 годин тому
CAR-T Cell Therapy for Transformed Follicular Lymphoma | Matthew Cortese, MD | #ASH24
Bispecific Antibodies for Diffuse large B-cell lymphoma with Lorenzo Falchi, MD
Переглядів 66День тому
Bispecific Antibodies for Diffuse large B-cell lymphoma with Lorenzo Falchi, MD
Adding a FLT3 Inhibitor May Improve Chemo Efficacy for Newly Diagnosed AML | Musa Yilmaz, MD| #ASH24
Переглядів 4614 днів тому
Adding a FLT3 Inhibitor May Improve Chemo Efficacy for Newly Diagnosed AML | Musa Yilmaz, MD| #ASH24
Real-World Impact of CAR-T Therapy on DLBCL: Insights & Future Research | Lisa Herms, PhD | #ASH24
Переглядів 1414 днів тому
Real-World Impact of CAR-T Therapy on DLBCL: Insights & Future Research | Lisa Herms, PhD | #ASH24
Novel CAR-T Attacks New Target in Relapsed LBCL | Anne Kramer, MD, PhD | #ASH24
Переглядів 1614 днів тому
Novel CAR-T Attacks New Target in Relapsed LBCL | Anne Kramer, MD, PhD | #ASH24
Fludarabine vs. Bendamustine Lymphodepletion Prior to CAR-T for LBCL | Alaa Ali, MD | #ASH24
Переглядів 2514 днів тому
Fludarabine vs. Bendamustine Lymphodepletion Prior to CAR-T for LBCL | Alaa Ali, MD | #ASH24
Rituximab for Low Tumor Burden Follicular Lymphoma | Noriko Fukuhara MD, PhD | #ASH24
Переглядів 1914 днів тому
Rituximab for Low Tumor Burden Follicular Lymphoma | Noriko Fukuhara MD, PhD | #ASH24
I love this guy! Gr8 Doctor!
My doctor tried a kind of immuneo therapy on mine three years ago but it didn’t do anything.
Plz any cure for colon cancer to many children dying from thet plz help them the are children
Sir pls do somthing and help the peopel i thing FDA has the cancer cure plz help children
Thank you so much for posting this Dr. Joanna Rhodes . It gives so much relevant information
Hi, hope u r doing good. I was diagnosed with cancer{(aml [inv16(16:16)} and doctor advised for bmt, so i did(haplo). Now, biopsy report is normal but mrd is positive with 227 aml copies. What should i do now?
Clearest insight I have found thank you
We're so glad you found this recording helpful. We have a variety of additional follicular lymphoma resources you can access by visiting our website: www.healthtree.org/follicular-lymphoma/community
Very nice!
Thanks for the forecast! Could you help me with something unrelated: I have a SafePal wallet with USDT, and I have the seed phrase. (behave today finger ski upon boy assault summer exhaust beauty stereo over). What's the best way to send them to Binance?
you go then!
Sir, what to do for hypo plastic MDS del 20q?
😊
Wise ... live each day as if it is your first ... and never give up hope!
Thank you for this advice Dr Chavez.
Hi Doctor, do you treat autoimmune hemolytic Anemia?
That is very promising,if the drug is 10 times stronger than venetoclax maybe that combination will offer a cure to some patients.
Absolutely terrific presentation by Dr Thompson! As a CLL-Small Cell B, I have just started Rx with Brukinsa for very bulky Axillary nodes. On the lookout for potential infections!
What will be the best therapy for MDS del 20q?.please suggest me
My momma was saved by this very treatment! Thank you Dr.Strati and your team! We are forever grateful.
This is amazing. We're so glad to hear a little bit about your mom's story!
*Promo sm*
Hope is allways available... God bless your efforts...
My dad is 67, turns 68 Feb 5th. He has non-small cell lung cancer and AML. He decided to do no treatment, and he has been told he has less than 6 months. He's refusing hospice, and as his daughter that lives in the home with him, all the responsibility is put on me. He also doesn't want to believe his pain is from the cancer. He believes he might not die or is hopeful he won't. This has been very hard to deal with. Any advice would be helpful.
Thank you for watching! I'm sorry to hear about your father's diagnosis. Being a caregiver in this situation is a big responsibility and can feel very overwhelming. We have several articles/events on caregiving that might be helpful. Reach out to me at mary@healthtree.org and I can share those resources with you!
@@HealthTreeforbloodcancers Thank you I will.
Exciting.
So amazing!!!!!
Well done, Dr. Mannis. Thanks.
We are glad you enjoyed this presentation!
Thank you for making the video
found out I have AML FTL3 in july and I go for a BMT after thanksgiving. I am scared to death